Please login to the form below

Biosimilars - the Brexit of the pharmaceutical industry?

In this article, Senior Consultant Jenna Earl explains what factors influence the uptake of biosimilars in the UK, comparing them to the same principles that help us navigate the complexities of Britain exiting the EU (Brexit).
Despite availability of biosimilars for nearly a decade, uptake in the UK is still lagging behind other EU markets, leading to the recent formation of the British Biosimilars Association (BBA) - part of the British Generic Manufacturers Association (BGMA). Biosimilars are undoubtedly a hot topic for providers of branded biologic medicines, biosimilar suppliers themselves, and the payers, healthcare professionals and patients involved in biologic treatment. Much like the EU referendum, they feature regularly in the news - with spectators waiting anxiously, in some cases eagerly, for a change that could alter the treatment landscape for several significant therapy areas. To understand the factors influencing the uptake of biosimilars you could apply the same principles as you would to navigating the complexities of Britain exiting the EU (Brexit).

1. Control is in the hands of the people

Britain's relationship with the EU will be decided by a referendum, placing the decision in the hands of the people. In the UK, the decision to prescribe a biosimilar is still largely down to the healthcare professional (HCP) but, if this were to change, impact on biologic markets could be dramatic. Despite NICE recommending biosimilars ahead of branded biologics in several disease areas, this does not appear to be happening in clinical practice. The next step for governing bodies to ensure biosimilars are prioritised in the treatment pathway is substitution, replacing a branded biologic with its corresponding biosimilar at point of dispensing; a move that would result in a huge uplift in biosimilar use. Arguably, the reason this hasn’t happened yet is that the financial gain generated by such a move does not yet outweigh the repercussions of reducing the role of the HCP in such an important decision. But with increasing pressure on the NHS to make cost savings and expect greater value from treatments, this could change in the future. 

Read the full article on the Blue Latitude Health blog

14th June 2016

Share

Tags

Company Details

Blue Latitude Health

+44 203 328 1840

Contact Website

Address:
Blue Latitude Health
Crusader House
145-157 St John Street
London
EC1V 4QJ
United Kingdom

Latest content on this profile

Culture cannot be global: doing business outside your comfort zone
Dorottya Okros of Blue Latitude Health talks through the common communication and negotiation pitfalls of working with Eastern Europe and the CIS for British presenters.
Blue Latitude Health
Using service design to improve patients’ quality of life
Customer Experience Consultant Eimear Power talks through the process of developing Orello, a service for metastatic prostate cancer patients and their loved ones, in collaboration with Janssen.
Blue Latitude Health
Precision medicine and the changing role of the healthcare professional
The growth of precision medicine introduces a shift away from treating the population as a whole, to treating each patient as an individual. How does this change the role of the healthcare professional (HCP) in the patient journey? Associate Consultant Ditte Funding discusses challenges and opportunities.
Blue Latitude Health
Caring for prostate cancer patients
Although not without its challenges, the appropriate care and support available to patients with prostate cancer is gradually evolving. It’s important not to overlook the all too often ‘unsung heroes’ of prostate cancer; those who care for the patients. Associate Consultant Frances Peters takes a look at the issues and concerns facing the caregivers of those with prostate cancer.
Blue Latitude Health
Marketing strategy in complex environments
Age-old treatment protocols are being replaced with new and innovative treatment paradigms that will revolutionise the healthcare industry for years to come. Kulveer Singh and Mark Assenti talk through what this means for pharma strategists and their product lines.
Blue Latitude Health
Influence mapping to improve the efficiency and effectiveness of your messaging
As companies work to find innovative marketing techniques to cut through the noise, influence mapping has seen an increase in popularity. Associate Consultant Pany Koizi talks through how to get the most out of the influence mapping process.
Blue Latitude Health